Terms: = Prostate cancer AND FBXW7, AGO, 55294, ENSG00000109670, FLJ11071, SEL-10, CDC4, FBXW6, SEL10, FBW7, DKFZp686F23254, FBX30 AND Treatment
184 results:
1. A systematic review of nanocarriers for treatment of urologic cancers.
Wang AJY; Yan C; Reike MJ; Black PC; Contreras-Sanz A
Urol Oncol; 2024 Apr; 42(4):75-101. PubMed ID: 38161104
[TBL] [Abstract] [Full Text] [Related]
2. Clinical Efficacy and Openness to New Challenges of Low Dose Rate Brachytherapy for prostate cancer.
Kato M; Higashi S; Sugino Y; Kajiwara S; Tanaka S; Kitano G; Yamashita Y; Ogura Y; Tachibana H; Kojima T; Inoue T
Curr Oncol; 2023 Nov; 30(11):9824-9835. PubMed ID: 37999133
[TBL] [Abstract] [Full Text] [Related]
3. Lifetime Follow-Up of a Patient with Metastatic prostate cancer Undergoing Multiple Surgical Resections: A Case Report.
Nanashima A; Nagayasu T; Yamasaki N; Tsuchiya T; Matsumoto K; Tagawa T; Arai J
Am J Case Rep; 2023 Nov; 24():e941668. PubMed ID: 37939016
[TBL] [Abstract] [Full Text] [Related]
4. Adenocarcinoma involving the urinary bladder.
Wang P; Joiner M; Dzul S; Miller SR
BMJ Case Rep; 2023 Jul; 16(7):. PubMed ID: 37463778
[TBL] [Abstract] [Full Text] [Related]
5. SENHANCE ROBOTIC RADICAL prostateCTOMY.
Kuliš T; Hudolin T; Penezić L; Zekulić T; Saić H; Sambolić T; Bačak Kocman I; Goluža E; Knežević N; Kaštelan Ž
Acta Clin Croat; 2022 Oct; 61(Suppl 3):45-50. PubMed ID: 36938559
[TBL] [Abstract] [Full Text] [Related]
6. Long-term survival trends in solid cancers in the Nordic countries marking timing of improvements.
Hemminki K; Försti A; Liska V; Kanerva A; Hemminki O; Hemminki A
Int J Cancer; 2023 May; 152(9):1837-1846. PubMed ID: 36571455
[TBL] [Abstract] [Full Text] [Related]
7. Celebrating 80 years anniversary of radioiodine for use in thyroid cancer and perspectives for theranostics.
Hertz B; Watabe T; Baum RP
Ann Nucl Med; 2022 Dec; 36(12):1007-1009. PubMed ID: 36346502
[TBL] [Abstract] [Full Text] [Related]
8. Health influence of SARS-CoV-2 (COVID-19) on cancer: a review.
Parise R; Li YE; Nadar RM; Ramesh S; Ren J; Govindarajulu MY; Moore T; Dhanasekaran M
Acta Biochim Biophys Sin (Shanghai); 2022 Oct; 54(10):1395-1405. PubMed ID: 36269132
[TBL] [Abstract] [Full Text] [Related]
9. Imaging-guided targeted radionuclide tumor therapy: From concept to clinical translation.
Sun J; Huangfu Z; Yang J; Wang G; Hu K; Gao M; Zhong Z
Adv Drug Deliv Rev; 2022 Nov; 190():114538. PubMed ID: 36162696
[TBL] [Abstract] [Full Text] [Related]
10. An overview of chemotoxicity and radiation toxicity in cancer therapy.
Yazbeck V; Alesi E; Myers J; Hackney MH; Cuttino L; Gewirtz DA
Adv Cancer Res; 2022; 155():1-27. PubMed ID: 35779872
[TBL] [Abstract] [Full Text] [Related]
11. Development of cancer Immunotherapies.
DeLucia DC; Lee JK
Cancer Treat Res; 2022; 183():1-48. PubMed ID: 35551655
[TBL] [Abstract] [Full Text] [Related]
12. Impact of next-generation hormonal agents on treatment patterns among patients with metastatic hormone-sensitive prostate cancer: a real-world study from the United States, five European countries and Japan.
Leith A; Ribbands A; Kim J; Clayton E; Gillespie-Akar L; Yang L; Ghate SR
BMC Urol; 2022 Mar; 22(1):33. PubMed ID: 35277153
[TBL] [Abstract] [Full Text] [Related]
13. OTUD6A promotes prostate tumorigenesis via deubiquitinating Brg1 and AR.
Fu X; Zhao J; Yu G; Zhang X; Sun J; Li L; Yin J; Niu Y; Ren S; Zhu Y; Xu B; Huang L
Commun Biol; 2022 Mar; 5(1):182. PubMed ID: 35233061
[TBL] [Abstract] [Full Text] [Related]
14. The modulatory role of internet-supported mindfulness-based cognitive therapy on extracellular vesicles and psychological distress in people who have had cancer: a protocol for a two-armed randomized controlled study.
Pereira DR; Silva ER; Carvalho-Maia C; Monteiro-Reis S; Lourenço C; Calisto R; Teixeira RJ; Carlson LE; Bart G; Vainio SJ; Sales MGF; Jerónimo C; Henrique R
Trials; 2022 Feb; 23(1):118. PubMed ID: 35123569
[TBL] [Abstract] [Full Text] [Related]
15. Methionine Restriction: Ready for Prime Time in the cancer Clinic?
Yamamoto J; Han Q; Simon M; Thomas D; Hoffman RM
Anticancer Res; 2022 Feb; 42(2):641-644. PubMed ID: 35093861
[TBL] [Abstract] [Full Text] [Related]
16. Targeting the IGF-1R in prostate and colorectal cancer: reasons behind trial failure and future directions.
Tufail M; Wu C
Ther Deliv; 2022 Mar; 13(3):167-186. PubMed ID: 35029130
[TBL] [Abstract] [Full Text] [Related]
17. High-resolution magic angle spinning NMR for intact biological specimen analysis: Initial discovery, recent developments, and future directions.
Cheng LL
NMR Biomed; 2023 Apr; 36(4):e4684. PubMed ID: 34962004
[TBL] [Abstract] [Full Text] [Related]
18. Side effects of theragnostic agents currently employed in clinical practice.
Rizzo A; Annunziata S; Salvatori M
Q J Nucl Med Mol Imaging; 2021 Dec; 65(4):315-326. PubMed ID: 34881848
[TBL] [Abstract] [Full Text] [Related]
19. Extracellular vesicles as a source of prostate cancer biomarkers in liquid biopsies: a decade of research.
Ramirez-Garrastacho M; Bajo-Santos C; Line A; Martens-Uzunova ES; de la Fuente JM; Moros M; Soekmadji C; Tasken KA; Llorente A
Br J Cancer; 2022 Feb; 126(3):331-350. PubMed ID: 34811504
[TBL] [Abstract] [Full Text] [Related]
20. Evolution of Focal Therapy in prostate cancer: Past, Present, and Future.
Arcot R; Polascik TJ
Urol Clin North Am; 2022 Feb; 49(1):129-152. PubMed ID: 34776047
[TBL] [Abstract] [Full Text] [Related]
[Next]
